Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Cholangiocarcinoma 6Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Digestive System Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

Fluorodeoxyglucose F18 7Irinotecan 4Fluorouracil 4Cyclophosphamide 4Bevacizumab 4toripalimab 3pembrolizumab 3olaparib 3Radiosurgery 3Cisplatin 3Capecitabine 3vistusertib 2tislelizumab 2spartalizumab 2fludarabine 2atezolizumab 2apatinib 2Temozolomide 2Technetium 2Specimen Handling 2Sirolimus 2Radiotherapy 2Proton Therapy 2Paclitaxel 2Leucovorin 2Letrozole 2Hydroxychloroquine 2Everolimus 2Drug Therapy 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumor × pemigatinib × Clear all
NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Tianjin Medical University Second Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡